• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肾脏病患者的内皮细胞微颗粒与全身补体激活。

Endothelial Microparticles and Systemic Complement Activation in Patients With Chronic Kidney Disease.

机构信息

Division of Nephrology, Carver College of Medicine University of Iowa, Iowa City, IA

Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Center, Aurora, CO.

出版信息

J Am Heart Assoc. 2018 Jul 13;7(14):e007818. doi: 10.1161/JAHA.117.007818.

DOI:10.1161/JAHA.117.007818
PMID:30006493
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6064828/
Abstract

BACKGROUND

Endothelial microparticles are associated with chronic kidney disease (CKD) and complement activation. We hypothesized that the complement pathway is activated in patients with CKD via endothelial microparticles and that complement activation correlates with endothelial dysfunction in CKD.

METHODS AND RESULTS

We analyzed complement data of 30 healthy subjects, 30 patients with stage III/IV CKD, and 30 renal transplant recipients with stage III/IV CKD, evaluating the potential correlation of complement fragments with brachial artery flow-mediated dilation, Chronic Kidney Disease Epidemiology Collaboration glomerular filtration rate, and urinary albumin/creatinine ratio. Endothelial microparticles were characterized via proteomic analysis and compared between study groups. Complement fragment Ba was significantly increased in CKD and post-kidney transplant CKD. Plasma Ba levels correlated significantly with lower brachial artery flow-mediated dilation, lower Chronic Kidney Disease Epidemiology Collaboration glomerular filtration rate, and higher urinary albumin/creatinine ratio. Factor D levels were significantly higher in the plasma microparticles of patients with CKD versus healthy controls. Plasma microparticles isolated from patients with CKD and containing factor D activated the alternative pathway in vitro.

CONCLUSION

The alternative complement pathway is activated in CKD and correlates with endothelial dysfunction and markers of CKD. Future studies are needed to evaluate whether endothelial microparticles with increased factor D play a pathologic role in CKD-associated vascular disease.

CLINICAL TRIAL REGISTRATION

URL: http://www.clinicaltrials.gov. Unique identifier: NCT02230202.

摘要

背景

内皮微粒与慢性肾脏病(CKD)和补体激活有关。我们假设 CKD 患者的补体途径通过内皮微粒被激活,并且补体激活与 CKD 中的内皮功能障碍相关。

方法和结果

我们分析了 30 名健康受试者、30 名 III/IV 期 CKD 患者和 30 名 III/IV 期 CKD 肾移植受者的补体数据,评估补体片段与肱动脉血流介导的扩张、慢性肾脏病流行病学合作肾小球滤过率和尿白蛋白/肌酐比值的潜在相关性。通过蛋白质组学分析对内皮微粒进行了特征描述,并将其与研究组进行了比较。CKD 和肾移植后 CKD 患者的补体片段 Ba 显著增加。血浆 Ba 水平与较低的肱动脉血流介导的扩张、较低的慢性肾脏病流行病学合作肾小球滤过率和较高的尿白蛋白/肌酐比值显著相关。与健康对照组相比,CKD 患者的血浆微粒中因子 D 水平显著升高。从 CKD 患者中分离出的含有因子 D 的血浆微粒在体外激活了替代途径。

结论

替代补体途径在 CKD 中被激活,并与内皮功能障碍和 CKD 标志物相关。需要进一步研究来评估是否具有增加的因子 D 的内皮微粒在 CKD 相关血管疾病中发挥病理作用。

临床试验注册

网址:http://www.clinicaltrials.gov。唯一标识符:NCT02230202。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/6064828/52b8c35bb204/JAH3-7-e007818-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/6064828/3e20858d1fc2/JAH3-7-e007818-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/6064828/ee60683d48ab/JAH3-7-e007818-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/6064828/ebf5f207b060/JAH3-7-e007818-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/6064828/bd101b73f913/JAH3-7-e007818-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/6064828/52b8c35bb204/JAH3-7-e007818-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/6064828/3e20858d1fc2/JAH3-7-e007818-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/6064828/ee60683d48ab/JAH3-7-e007818-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/6064828/ebf5f207b060/JAH3-7-e007818-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/6064828/bd101b73f913/JAH3-7-e007818-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4161/6064828/52b8c35bb204/JAH3-7-e007818-g005.jpg

相似文献

1
Endothelial Microparticles and Systemic Complement Activation in Patients With Chronic Kidney Disease.慢性肾脏病患者的内皮细胞微颗粒与全身补体激活。
J Am Heart Assoc. 2018 Jul 13;7(14):e007818. doi: 10.1161/JAHA.117.007818.
2
Endothelium-Dependent and -Independent Vascular Function in Advanced Chronic Kidney Disease.晚期慢性肾脏病中的血管内皮依赖性和非依赖性功能。
Clin J Am Soc Nephrol. 2017 Oct 6;12(10):1588-1594. doi: 10.2215/CJN.12811216. Epub 2017 Aug 7.
3
Endothelial dysfunction correlates with exaggerated exercise pressor response during whole body maximal exercise in chronic kidney disease.在慢性肾病患者进行全身最大运动时,内皮功能障碍与运动升压反应过度相关。
Am J Physiol Renal Physiol. 2017 May 1;312(5):F917-F924. doi: 10.1152/ajprenal.00603.2016. Epub 2017 Mar 8.
4
Increased concentrations of platelet- and endothelial-derived microparticles in patients with myocardial infarction and reduced renal function- a descriptive study.在心肌梗死和肾功能降低的患者中,血小板和内皮细胞衍生的微颗粒浓度增加——一项描述性研究。
BMC Nephrol. 2019 Mar 1;20(1):71. doi: 10.1186/s12882-019-1261-x.
5
Endothelial function and oxidative stress in chronic kidney disease of varying severity and the effect of acute hemodialysis.不同严重程度慢性肾脏病的内皮功能和氧化应激以及急性血液透析的影响。
Ren Fail. 2011;33(4):411-7. doi: 10.3109/0886022X.2011.568138.
6
Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4.慢性肾脏病 3 至 4 期患者的亚临床动脉粥样硬化、内皮功能与血清炎症标志物。
Angiology. 2014 May;65(5):443-9. doi: 10.1177/0003319713483000. Epub 2013 Apr 7.
7
Relationship between Endothelial Dysfunction and Prevalence of Chronic Kidney Disease: The Circulatory Risk in Communities Study (CIRCS).内皮功能障碍与慢性肾脏病患病率的关系:社区中的循环风险研究 (Circulatory Risk in Communities Study, CIRCS)。
J Atheroscler Thromb. 2021 Jun 1;28(6):622-629. doi: 10.5551/jat.56424. Epub 2020 Sep 2.
8
Endothelial dysfunction and complement activation are independently associated with disease duration in patients with systemic vasculitis.内皮功能障碍和补体激活与系统性血管炎患者的疾病持续时间独立相关。
Microvasc Res. 2024 Jul;154:104692. doi: 10.1016/j.mvr.2024.104692. Epub 2024 May 4.
9
Assessment of endothelial dysfunction: the role of symmetrical dimethylarginine and proinflammatory markers in chronic kidney disease and renal transplant recipients.内皮功能障碍评估:对称二甲基精氨酸和促炎标志物在慢性肾脏病和肾移植受者中的作用。
Dis Markers. 2013;35(3):173-80. doi: 10.1155/2013/306908. Epub 2013 Aug 5.
10
Paricalcitol and endothelial function in chronic kidney disease trial.帕立骨化醇和慢性肾脏病试验中的内皮功能。
Hypertension. 2014 Nov;64(5):1005-11. doi: 10.1161/HYPERTENSIONAHA.114.03748. Epub 2014 Aug 4.

引用本文的文献

1
Plasma complement proteins as biomarkers and therapeutic targets in chronic kidney disease: a Mendelian randomization analysis.血浆补体蛋白作为慢性肾脏病的生物标志物和治疗靶点:孟德尔随机化分析
Ren Fail. 2025 Dec;47(1):2525473. doi: 10.1080/0886022X.2025.2525473. Epub 2025 Jul 17.
2
Chronic kidney disease enhances alternative pathway activity: a new paradigm.慢性肾脏病增强替代途径活性:一种新范式。
J Clin Invest. 2025 May 1;135(9). doi: 10.1172/JCI188353.
3
Exploring the Plasma Proteome: Identifying Hub Proteins linking Aging, Homeostasis, and Organ Function.

本文引用的文献

1
Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.小分子因子 D 抑制剂可选择性阻断阵发性夜间血红蛋白尿和非典型溶血尿毒症综合征中补体的替代途径。
Haematologica. 2017 Mar;102(3):466-475. doi: 10.3324/haematol.2016.153312. Epub 2016 Nov 3.
2
IL-1 Inhibition and Vascular Function in CKD.白细胞介素-1抑制与慢性肾脏病中的血管功能
J Am Soc Nephrol. 2017 Mar;28(3):971-980. doi: 10.1681/ASN.2016040453. Epub 2016 Sep 19.
3
Vascular Function and Uric Acid-Lowering in Stage 3 CKD.
探索血浆蛋白质组:鉴定连接衰老、内环境稳定和器官功能的枢纽蛋白。
Int J Med Sci. 2025 Feb 10;22(5):1109-1123. doi: 10.7150/ijms.107750. eCollection 2025.
4
Urine Complement Factor Ba Identifies Persistent Acute Kidney Injury and Organ Failures in Critically Ill Adults.尿补体因子Ba可识别危重症成年患者的持续性急性肾损伤和器官功能衰竭。
Kidney Int Rep. 2024 Nov 25;10(2):424-431. doi: 10.1016/j.ekir.2024.11.030. eCollection 2025 Feb.
5
The Janus-faced nature of complement in hemodialysis: interplay between complement, inflammation, and bioincompatibility unveiling a self-amplifying loop contributing to organ damage.血液透析中补体的双面性:补体、炎症和生物不相容性之间的相互作用揭示了一个自我放大的循环,导致器官损伤。
Front Nephrol. 2024 Dec 3;4:1455321. doi: 10.3389/fneph.2024.1455321. eCollection 2024.
6
Mediterranean Diet Pattern: Potential Impact on the Different Altered Pathways Related to Cardiovascular Risk in Advanced Chronic Kidney Disease.地中海饮食模式:对晚期慢性肾脏病相关心血管风险改变途径的潜在影响。
Nutrients. 2024 Oct 31;16(21):3739. doi: 10.3390/nu16213739.
7
Hemoincompatibility in Hemodialysis-Related Therapies and Their Health Economic Perspectives.血液透析相关治疗中的血液不相容性及其健康经济学视角。
J Clin Med. 2024 Oct 16;13(20):6165. doi: 10.3390/jcm13206165.
8
Role of complement factor D in cardiovascular and metabolic diseases.补体因子 D 在心血管和代谢疾病中的作用。
Front Immunol. 2024 Oct 2;15:1453030. doi: 10.3389/fimmu.2024.1453030. eCollection 2024.
9
Proteomic Correlates and Prognostic Significance of Kidney Injury in Heart Failure With Preserved Ejection Fraction.心脏射血分数保留的心力衰竭患者的肾脏损伤的蛋白质组学相关性及其预后意义。
J Am Heart Assoc. 2024 Sep 3;13(17):e033660. doi: 10.1161/JAHA.123.033660. Epub 2024 Aug 29.
10
The role of complement in kidney disease.补体在肾脏疾病中的作用。
Nat Rev Nephrol. 2023 Dec;19(12):771-787. doi: 10.1038/s41581-023-00766-1. Epub 2023 Sep 21.
3期慢性肾脏病患者的血管功能与尿酸降低
J Am Soc Nephrol. 2017 Mar;28(3):943-952. doi: 10.1681/ASN.2016050521. Epub 2016 Sep 12.
4
Targeting the complement cascade: novel treatments coming down the pike.靶向补体级联反应:即将出现的新疗法。
Kidney Int. 2016 Oct;90(4):746-52. doi: 10.1016/j.kint.2016.04.018. Epub 2016 Jun 18.
5
Extracellular vesicle isolation and characterization: toward clinical application.细胞外囊泡的分离与表征:迈向临床应用
J Clin Invest. 2016 Apr 1;126(4):1152-62. doi: 10.1172/JCI81129.
6
Phospholipid Binding Protein C Inhibitor (PCI) Is Present on Microparticles Generated In Vitro and In Vivo.磷脂结合蛋白C抑制剂(PCI)存在于体外和体内产生的微粒上。
PLoS One. 2015 Nov 18;10(11):e0143137. doi: 10.1371/journal.pone.0143137. eCollection 2015.
7
The alternative complement pathway is longitudinally associated with adverse cardiovascular outcomes. The CODAM study.替代补体途径与不良心血管结局呈纵向相关。CODAM 研究。
Thromb Haemost. 2016 Jan;115(2):446-57. doi: 10.1160/TH15-05-0439. Epub 2015 Oct 8.
8
Complement Activation in Patients with Focal Segmental Glomerulosclerosis.局灶节段性肾小球硬化患者的补体激活
PLoS One. 2015 Sep 3;10(9):e0136558. doi: 10.1371/journal.pone.0136558. eCollection 2015.
9
Complement activation in progressive renal disease.进行性肾脏疾病中的补体激活。
World J Nephrol. 2015 Feb 6;4(1):31-40. doi: 10.5527/wjn.v4.i1.31.
10
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.Bardoxolone methyl 在 2 型糖尿病和 4 期慢性肾脏病中的应用。
N Engl J Med. 2013 Dec 26;369(26):2492-503. doi: 10.1056/NEJMoa1306033. Epub 2013 Nov 9.